44 related articles for article (PubMed ID: 10734033)
21. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.
Sinagra E; Perricone G; D'Amico M; Tinè F; D'Amico G
Aliment Pharmacol Ther; 2014 Mar; 39(6):557-68. PubMed ID: 24461301
[TBL] [Abstract][Full Text] [Related]
22. Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis.
Aguilar-Olivos N; Motola-Kuba M; Candia R; Arrese M; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
Ann Hepatol; 2014; 13(4):420-8. PubMed ID: 24927613
[TBL] [Abstract][Full Text] [Related]
23. [Combined alpha and beta blockers in the therapy of cardiovascular diseases].
Tavciovski D; Romanović R; Bosković S; Duran P; Matunović R
Vojnosanit Pregl; 2002; 59(4):405-10. PubMed ID: 12235748
[No Abstract] [Full Text] [Related]
24. Carvedilol.
Frishman WH
N Engl J Med; 1998 Dec; 339(24):1759-65. PubMed ID: 9845712
[No Abstract] [Full Text] [Related]
25. Pharmacologic prevention of variceal bleeding and rebleeding.
Baiges A; Hernández-Gea V; Bosch J
Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of carvedilol for the treatment of portal hypertension.
Hemstreet BA
Pharmacotherapy; 2004 Jan; 24(1):94-104. PubMed ID: 14740791
[TBL] [Abstract][Full Text] [Related]
27. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Li T; Ke W; Sun P; Chen X; Belgaumkar A; Huang Y; Xian W; Li J; Zheng Q
BMJ Open; 2016 May; 6(5):e010902. PubMed ID: 27147389
[TBL] [Abstract][Full Text] [Related]
28. Beta blockers and cirrhosis, 2016.
Mandorfer M; Reiberger T
Dig Liver Dis; 2017 Jan; 49(1):3-10. PubMed ID: 27717792
[TBL] [Abstract][Full Text] [Related]
29. The role of carvedilol in the management of portal hypertension.
Tripathi D; Hayes PC
Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):905-11. PubMed ID: 20093937
[TBL] [Abstract][Full Text] [Related]
30. Carvedilol in the treatment of portal hypertension.
Al-Ghamdi H
Saudi J Gastroenterol; 2011; 17(2):155-8. PubMed ID: 21372358
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamic profile of carvedilol.
van Zwieten PA
Cardiology; 1993; 82 Suppl 3():19-23. PubMed ID: 8106159
[TBL] [Abstract][Full Text] [Related]
32. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction.
Kopecky SL
Am J Cardiol; 2006 Oct; 98(8):1115-9. PubMed ID: 17027583
[TBL] [Abstract][Full Text] [Related]
33. [Alpha beta-blockers for patients with hypertension].
Mizuta Y; Imaizumi T
Nihon Rinsho; 2006 Aug; 64 Suppl 6():305-9. PubMed ID: 16981560
[No Abstract] [Full Text] [Related]
34. Impact of carvedilol on the serum lipid profile.
Sharp RP; Sirajuddin R; Sharief IM
Ann Pharmacother; 2008 Apr; 42(4):564-71. PubMed ID: 18364407
[TBL] [Abstract][Full Text] [Related]
35. Carvedilol outclasses the other beta-blockers.
Cardiovasc J S Afr; 2001; 12(2):120-1. PubMed ID: 11474696
[No Abstract] [Full Text] [Related]
36. Pharmacologic management of portal hypertension.
Berzigotti A; Bosch J
Clin Liver Dis; 2014 May; 18(2):303-17. PubMed ID: 24679496
[TBL] [Abstract][Full Text] [Related]
37. Beta-receptor blocking treatment in portal hypertension.
Olsson R
Scand J Gastroenterol; 1990 Jul; 25(7):641-6. PubMed ID: 1975704
[No Abstract] [Full Text] [Related]
38. Beta-adrenergic blockers for portal hypertension. Lessons from animal models.
Sikuler E
J Hepatol; 1991 Mar; 12(2):133-5. PubMed ID: 1675643
[No Abstract] [Full Text] [Related]
39. [Not Available].
Kleefisch M; Lange C; Wedemeyer H
MMW Fortschr Med; 2019 Nov; 161(20):39. PubMed ID: 31773605
[No Abstract] [Full Text] [Related]
40. An advance in the treatment of portal hypertension?
Wong F; Blendis L
Gastroenterology; 2000 Apr; 118(4):802-3. PubMed ID: 10734033
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
